Effect of chronic antioxidant therapy with superoxide dismutase-mimetic Drug, Tempol, on progression of renal disease in rats with renal mass reduction

Nephron - Experimental Nephrology

Volumn 112, Issue 1, 2009, Pages

  Quiroz, Yasmir ^a   Ferrebuz, Atilio ^a   Vaziri, Nosratola D ^b   Rodriguez Iturbe, Bernardo ^a,c,d  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD DEL ZULIA   (Venezuela)

^d HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

Author keywords

Chronic renal failure; Oxidative stress; Renal ablation; Superoxide dismutase

Indexed keywords

3 NITROTYROSINE; HYDROGEN PEROXIDE; MALONALDEHYDE; SUPEROXIDE; TEMPOL; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; GLOMERULAR DYSFUNCTION; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY MASS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MICROSCOPY; NEPHRECTOMY; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RAT; SHAM PROCEDURE; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; CYCLIC N-OXIDES; DISEASE PROGRESSION; KIDNEY DISEASES; MALE; NEPHRECTOMY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SPIN LABELS;

EID: 63349109629     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210577     Document Type: Article

References (66)

1. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, Warnock DG, Vinicor F: Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006; 3:A57:1-6.
2. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12:1315-1325.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
4. Vaziri ND: Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469-473.
5. Vaziri ND, Rodriguez-Iturbe B: Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2007; 2: 582-593.
6. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Rodriguez-Iturbe B: Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323:85-93.
7. Sindhu RK, Ehdaie A, Farmand F, Dhaliwal KK, Nguyen T, Zhan CD, Roberts CK, Vaziri ND: Expression of catalase and glutathione peroxidase in renal insufficiency. Biochim Biophys Acta 2005; 1743:86-92.
8. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-720.
9. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E: Mycophenolate mofetil prevents the progression of renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55:945-955.
10. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-1519.
11. Fujihara CK, Antunes GR, Mattar AL, Malheiros DM, Vieira JM Jr, Zatz R: Chronic inhibition of nuclear factor-κB attenuates renal injury in the 5/6 renal ablation model. Am J Physiol Renal Physiol 2007; 292:F92-F99.
12. Tain YL, Freshour G, Dikalova A, Griendling K, Baylis C: Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 2007; 292:F1404-F1410.
13. Quiroz Y, Romero F, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B: Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression in rats with renal mass reduction. Am J Physiol, Renal Physiol 2008; 294:F336-F344.
14. Vaziri ND, Oveisi F, Reyes GA, Zhou XJ: Dysregulation of melatonin metabolism in chronic renal insufficiency: role of erythropoietin-deficiency anemia. Kidney Int 1996; 50: 653-656.
15. Soule BP, Hyodo F, Matsumoto KI, Simone NL, Cook JA, Krishna MC, Mitchell JB: The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007; 42:1632-1650.
16. 2α. Hypertension 1999; 33: 424-428.
17. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y: The SOD-mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 2004; 15: 306-415.
18. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001; 37: 781-786.
19. Vaziri ND, Ding Y, Ni Z: Compensatory upregulation of NO synthase isoforms in lead-induced hypertension: reversal by an SOD-mimetic drug. J Pharmacol Exp Ther 2001; 298: 679-685.
20. Guron GS, Grimberg ES, Basu S, Herlitz H: Acute effects of the superoxide dismutase mimetic tempol on split kidney function in two-kidney one-clip hypertensive rats. J Hy-pertens 2006; 24: 387-394.
21. Leach M, Frank S, Olbrich A, Pfeilschifter J, Thiemermann C: Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: effects of the superoxide anion radical scavenger, tempol, on organ injury. Br J Pharmacol 1998; 125:817-825.
22. Mota-Filipe H, McDonald MC, Cuzzocrea S, Thiemermann C: A membrane-permeable radical scavenger reduces the organ injury in hemorrhagic shock. Shock 1999; 12:255-261.
23. Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, Thiemermann C: Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 2000; 58:658-673.
24. Asaba K, Tojo A, Onozato ML, Goto A, Fujita T: Double-edged action of SOD mimetic in diabetic nephropathy. J Cardiovasc Pharmacol 2007; 49: 13-19.
25. Vaziri ND, Dicus M, Ho N, Sindhu R: Oxidative stress and dysregulation of superoxide dismutase and NAD(P)H oxidase in renal insufficiency. Kidney Int 2003; 63:179-185.
26. Linares E, Giorgio S, Augusto O: Inhibition of in vivo leishmanicidal mechanisms by tempol: nitric oxide down-regulation and oxidant scavenging. Free Radic Biol Med 2008; 44:1668-1676.
27. Williams JM, Pollock JS, Pollock DM: Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension 2004; 44: 770-775.
28. Tatchum-Talom R, Martin DS: Tempol improves vascular function in the mesenteric vascular bed of senescent rats. Can J Physiol Pharmacol 2004; 82: 200-207.
29. Sainz J, Wangensteen R, Rodríguez Gomez I, Moreno JM, Chamorro V Osuna A, Bueno P, Vargas F: Antioxidant enzymes and effects of tempol on the development of hypertension induced by nitric oxide inhibition. Am J Hypertens 2005; 18:871-877.
30. Bayorh MA, Mann G, Walton M, Eatman D: Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats. Clin Exp Hypertens 2006; 28: 121-132.
31. Asghar M, Lokhandwala MF: Antioxidant tempol lowers age-related increases in insulin resistance in Fischer 344 rats. Clin Exp Hypertens 2006; 28: 533-541.
32. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T: Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883.
33. Hayden MR, Chowdhury NA, Cooper SA, Whaley-Connell A, Habibi J, Witte L, Wiedmeyer C, Manrique CM, Lastra G, Ferrario C, Stump C, Sowers JR: Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2007; 292:F861-F867.
34. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y: Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003; 42:754-760.
35. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND: Evolution of renal interstitial inflammation and NF-kB activation in spontaneously hypertensive rats. Am J Nephrol 2004; 24: 587-594.
36. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V Quiroz Y, Mezzano S, Vaziri ND: Early and sustained inhibition of nuclear factor κB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315:51-57.
37. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282:F191-F201.
38. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann Biochem 1979; 95: 351-359.
39. Nava M, Romero F, Quiroz V, Bonet L, Rod-riguez-Iturbe B: Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol 2000; 279:F910-F918.
40. Briggs RT, Robinson JM, Karnovsky ML, Karnovsky MJ: Superoxide production by polymorphonuclear leukocytes. A cytochemical approach. Histochemistry 1986; 84: 371-378.
41. Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B: Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002; 283:F1132-F1141.
42. Rodriguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND: Mycophenolate mofetil ameliorates nephropathy in the obese Zuck-er rats. Kidney Int 2005; 68:1041-1047.
43. Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW: Intraglomerular platelet aggregation in experimental glomerulonephritis. Kidney Int 1990; 37: 1500 -1508 .
44. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B: Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003; 284:F447-F454.
45. Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, Ohnishi T, Sekimoto M, To-mita N, Shiozaki H, Monden M: Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem 1998; 46: 397- 403.
46. Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, Reckel-hoff JF, Granger JP: Role of reactive oxygen species in endothelin-induced hypertension. Hypertension 2003; 42:806-810.
47. Marwaha A, Lokhandwala MF: Tempol reduces oxidative stress and restores renal dopamine D1-like receptor-G protein coupling and function in hyperglycemic rats. Am J Physiol Renal Physiol 2006; 291:F58-F66.
48. Vaziri ND: Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 8(4 suppl 1):S74-S79.
49. Mitchell JB, Xavier S, DeLuca AM, Sowers AL, Cook JA, Krishna MC, Hahn SM, Russo A: A low-molecular-weight antioxidant decreases weight and lowers tumor incidence. Free Rad ic Biol Med 2003; 34: 93 -102 .
50. Kopkan L, Majid DS: Enhanced superoxide activity modulates renal function in NO-deficient hypertensive rats. Hypertension 2006; 47: 568-572.
51. Yanes L, Romero D, Iliescu R, Cucchiarelli VE, Fortepiani LA, Santacruz F, Bell W, Zhang H, Reckelhoff JF: Systemic arterial pressure response to two weeks of tempol therapy in SHR: involvement of NO, the R AS, and ox idative stress. Am J Physiol 2005; 288:R903-R908.
52. Gonçalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, Zatz R: Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a non-steroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286:F945-F954.
53. Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294:F1-F9.
54. Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A: Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci USA 1992; 89:5537-5541.
55. Vaz SM, Augusto O: Inhibition of myeloperoxidase-mediated protein nitration by tempol: kinetics, mechanism, and implications. Proc Natl Acad Sci USA 2008; 105:8191-8196.
56. Roveri A, Coassin M, Maiorino M, Zamburlini A, van Amsterdam FT, Ratti E, Ursini F: Effect of hydrogen peroxide on calcium homeostasis in smooth muscle cells. Arch Biochem Biophys 1992; 297: 265-270.
57. Thakali K, Davenport L, Fink GD, Watts SW: Pleiotropic effects of hydrogen peroxide in arteries and veins from normotensive and hypertensive rats. Hypertension 2006; 47: 482-487.
58. Gao YJ, Lee RM: Hydrogen peroxide is an endothelium-dependent contracting factor in rat rena l a r ter y. Br J Pharmacol 2005; 146: 1061-1068.
59. 2 increases production of constrictor prostaglandins in smooth muscle leading to enhanced arteriolar tone in type 2 diabetic mice. Am J Physiol 2007; 292:H649-H656.
60. Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ: New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1987; 79: 1379-1387.
61. Yoshioka T, Ichikawa I, Fogo A: Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormalit y. J Am Soc Nephrol 1991; 2: 902-912.
62. Vissers MC, Winterbourn CC: The effect of oxidants on neurtophil-mediated degradation of glomerular basement membrane collagen. Biochim Biophys Acta 1986; 889: 277-289.
63. Weiss SJ, Young J, LoBuglio AF, Slivka A, Nimeh NF: Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981; 68: 714 -721.
64. 2 counteracts t he vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol 2003; 285:R827-R833.
65. 2 leads to hypertension. Hypertension 2003; 42:25-30.
66. Kobayashi M, Sugiyama H, Wang DH, Toda N, Maeshima Y, Yamasaki Y, Masuoka N, Yamada M, K ira S, Mak ino H: Catala se deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int 2005; 68: 1018-1031.